Clinical trials: B-Non Hodgkin Lymphoma
Mature B-Cell Leukemia Burkitt Type, Burkitt Lymphoma (BL)
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.
Rituximab combined with a specific intensive chemotherapy is considered the standard treatment for newly diagnosed patients with mature B leukemia/lymphoma. However, the toxicity of this therapy is high.
- Conditions
- Mature B-Cell Leukemia Burkitt Type, Burkitt Lymphoma (BL), Unclassifiable Lymphoma Between DCBL and BL
- Trial name
- NCT05049473
- Testing
- Rituximab, Methotrexate, Dexamethasone
- Where
- 29 sites in Spain
- Volunteers
- 100 people
- Sponsor
- PETHEMA Foundation
B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse
CIK Cell Therapy for Relapsed or Refractory Acute B-Lymphoblastic Leukemia: Prognostic Impact on Patients With Early CAR-T Cell Dysfunction
This is a single-center, double-blind, randomized trial. Patients with relapsed or refractory acute B-lymphoblastic leukemia(r/r B-ALL) experiencing early functional exhaustion of CAR-T cells will be randomly allocated into three…
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoid Leukemia
- Trial name
- NCT06389305
- Testing
- peripheral blood lymphocytes, CIK cell
- Where
- China
- Volunteers
- 213 people
- Sponsor
- Beijing GoBroad Hospital
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Sargramostim in Reducing Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplantation for Hematologic Cancer or Aplastic Anemia
RATIONALE: Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy or…
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00053157
- Testing
- sargramostim
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Roswell Park Cancer Institute
Leukemia, Lymphoma
Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma
This is a multicenter study to assess the anti-tumour activity,to investigate the safety profile and to obtain additional pharmacokinetic information for Aplidin® given as 1-hour weekly IV infusion in patients with aggressive…
- Trial name
- NCT00884286
- Testing
- Aplidin®
- Where
- 12 sites in France, Italy and 4 more
- Volunteers
- 67 people
- Sponsor
- PharmaMar
Indolent Non Hodgkin's Lymphoma (iNHL), Chronic Lymphocytic Leukaemia (CLL)
Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)
The purpose of this study is to document the pharmacological treatment strategies used in treatment naïve and previously treated relapsed/refractory iNHL/CLL patients in the Middle East and North African (MENA) region.
- Trial name
- NADIR (NCT02273856)
- Where
- 8 sites in Jordan, Kuwait and 5 more
- Volunteers
- 25 people
- Sponsor
- Astellas Pharma International B.V.
AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas
This phase I trial studies the side effect and best dose of ibrutinib in combination with rituximab, etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride in treating patients with human…
- Conditions
- AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03220022
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
- Where
- 19 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma
The goal of this clinical research study is to see if high-dose chemotherapy (BEAM) and rituximab, given together with the new drug 90Y Zevalin, followed by a transplant of blood or marrow stem cells is safe.
- Trial name
- NCT01538472
- Testing
- Y Zevalin, In Zevalin, Rituxan
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
AIDS-related Lymphoma, HIV Infection
Optimization of Antiretroviral Therapy in Patients With AIDS-Related Lymphoma
The goal of this clinical trial is to evaluate the efficacy and safety of different antiretroviral therapy (ART) strategies in adults with AIDS-related lymphoma (ARL) receiving anti-lymphoma treatment.
- Trial name
- OPT-ARL (NCT07727642)
- Testing
- Oral Antiretroviral Therapy, albuvirtide, Cabotegravir/Rilpivirine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Public Health Clinical Center
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
The purpose of this study is to determine the most appropriate dose for the combination of ibrutinib and pembrolizumab and to see if the combination is active for the disease.
- Trial name
- NCT03153202
- Testing
- Ibrutinib, Pembrolizumab
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Joshua Brody
Myeloproliferative Disorders, Kidney Cancer
Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma
- Trial name
- NCT00787761
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Northside Hospital, Inc.
Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia
This study is designed to determine the recommended phase 2 dose (RP2D), and the safety, and efficacy of durvalumab as monotherapy and when given in combination with lenalidomide and rituximab; ibrutinib; or bendamustine and…
- Trial name
- FUSION NHL 001 (NCT02733042)
- Testing
- Durvalumab, Lenalidomide, Rituximab
- Where
- 66 sites in United States, France and 5 more
- Volunteers
- 106 people
- Sponsor
- Celgene
Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
RATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV) infection caused by a stem cell transplant.
- Conditions
- Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT01199562
- Testing
- infection prophylaxis and management, laboratory biomarker analysis, flow cytometry
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- City of Hope Medical Center
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphomas
A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin Lymphoma
This research study is evaluating a drug combination called Imprime PGG and Rituximab as a possible treatment for relapsed/refractory indolent B cell non-Hodgkin lymphomas (NHL).
- Trial name
- NCT02086175
- Testing
- Imprime PGG, Rituximab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Dana-Farber Cancer Institute
Recurrent B Acute Lymphoblastic Leukemia
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
This randomized phase III trial studies how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement…
- Trial name
- NCT02101853
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase, Blinatumomab
- Where
- 186 sites in United States, Australia and 3 more
- Volunteers
- 669 people
- Sponsor
- National Cancer Institute (NCI)
Marginal Zone Lymphoma
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
For marginal zone lymphoma (MZL) Rituximab in combination with conventional chemotherapy is widely used for those patients who fail local therapy or do not qualify for such.
- Trial name
- NCT04268277
- Testing
- Rituximab, Pembrolizumab
- Where
- 12 sites in Germany
- Volunteers
- 22 people
- Sponsor
- University of Ulm
Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma
ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma
This phase I/II trial finds out the best dose, possible benefits and/or side effects of ALX148 in combination with rituximab and lenalidomide in treating patients with indolent and aggressive B-cell non-Hodgkin lymphoma.
- Conditions
- Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma
- Trial name
- NCT05025800
- Testing
- CD47 Antagonist ALX148, Lenalidomide, Rituximab
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- M.D. Anderson Cancer Center
Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies
The purpose of this study is to determine if it is possible to treat relapsed or refractory lymphoid malignancies (Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia) with a new type of T cell-based…
- Conditions
- Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT04732845
- Testing
- Fully human anti CD19 CAR-T Cell Dose, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Benjamin Tomlinson
Diffuse Large B Cell Non-Hodgkin Lymphoma
A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL)
Prospective, multicenter, single arm, phase II study, to evaluate the efficacy of the combination rituximab-golcadomide as a chemo free approach in a population of older patients with new diagnosis of DLBCL, defined as frail…
- Trial name
- FIL_RICCO (NCT06835530)
- Testing
- Rituximab + Golcadomide (CC-99282)
- Where
- 20 sites in Italy
- Volunteers
- 47 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Waldenstrom's Macroglobulinemia, Lymphoplasmacytic Lymphoma
Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia
The purpose of this study is to evaluate how tumors in patients with Waldenstrom's macroglobulinemia respond to treatment with bortezomib (Velcade) and to see what effects (good and bad) it has on the cancer.
- Trial name
- NCT00142129
- Testing
- Bortezomib (Velcade)
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Dana-Farber Cancer Institute
Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma
This is a single center, non-randomized, open-label, phase 2 study to evaluate the efficacy and safety of CD19/22 CART cells combined with PD-1 Inhibitor in relapsed/refractory B Cell Lymphoma.
- Trial name
- NCT04539444
- Testing
- CD19/22 CART, Tislelizumab
- Where
- China
- Volunteers
- 18 people
- Sponsor
- The First Affiliated Hospital of Soochow University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.